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ABSTRACT 
 
Objective: The purpose of this study is to report the use of intravenous lipid emulsion (ILE) in dogs presenting 
with suspected tremorgenic mycotoxicosis based on signs of intoxication and known ingestion of mouldy food 
or compost. 
 
Background: ILE is being used for toxicoses associated with fat soluble agents. As tremorgenic mycotoxins are 
lipophilic in nature, the use of ILE may be of benefit in these patients.  
 
Methods: Medical records of all dogs examined at any Vets Now clinic between November 2012 and 
November 2016, in which ILE had been used, were reviewed and 53 cases were included in the study. 
 
Results: In 96% of cases there was clinical improvement recorded post ILE administration within a median time 
of 4 hours. No adverse effects were seen during the infusion or up to the time of discharge. 
 
Conclusion: The administration of ILE seems to be associated with a beneficial effect in the short term in dogs. 
Prospective evaluation of this therapy is warranted to further evaluate the use of ILE in these cases. 
 
INTRODUCTION 
 
Tremorgenic mycotoxicosis is a common intoxication in dogs, due to their indiscriminate eating habits. A 
presumptive diagnosis is made in most cases based upon history and clinical findings. Known ingestion of, or 
possible access to, mouldy food, garbage, or compost is highly suggestive (Barker et al., 2013). Signs usually 
occur within 30 minutes of ingestion, although rarely, can be delayed for several hours (Talcott, 2013). The 
most common signs of tremorgenic mycotoxin exposure reported to the Veterinary Poisons Information 
Service (VPIS) include ataxia, tremors, restlessness, hyperaesthesia, tachycardia and vomiting. In severe cases 
opisthotonus, seizures and coma can be seen. Signs can sometimes progress to hyperthermia, exhaustion, 
rhabdomyolysis, dehydration and hypoglycaemia. Clinical signs usually resolve gradually within 24-96 hours. 
Approximately 20 mycotoxins have been identified as tremorgens. Those most frequently reported to affect 
dogs are penitrem A and roquefortine C, which are produced by Penicillium spp (Eriksen et al., 2010). After 
ingestion, the tremorgenic mycotoxins present in contaminated food are thought to cross the blood-brain 
barrier due to lipophilic properties (Schell, 2000). Multiple mechanisms of action have been suggested for 
tremorgenic mycotoxins. Rats injected with penitrem A show marked increases in the release of gamma-
aminobutyric acid GABA, glutamate, and aspartate at cerebrocortical synapses (Norris et al., 1980). A similar 
interference with neurotransmission within the cerebellum is thought to be the reason behind the 
characteristic tremor in dogs (Eriksen et al., 2010);however, it is generallybelieved that the mechanism of 
action differs for each toxin involved in the exposure. Further researchis warranted to identify specific 
mechanisms of action. 
Treatment is symptomatic and supportive and usually involves gastrointestinal decontamination, management 
of neurological signs with muscle relaxants,anti-seizure drugs and management for hyperthermia as required. 
Due to the rapid absorption of mycotoxins and rapid onset of clinical signs, the window of opportunity to 
safely induce emesis is generally limited (Boysen et al., 2002; Crandell, 2006).Therefore, once clinical signs are 
appropriately controlled, gastric lavage should be considered in these cases. Activated charcoal with or 
without a cathartic may then be instilled through the gastric tube before it is removed to reduce toxin 
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exposure. There is evidence that the common mycotoxins are excreted in bile, suggesting the likelihood of 
hepatic recirculation (Puschner et al., 2009) and the need for repeated doses of activated charcoal over 2 to 3 
days. 
ILE was initially used to treat local anaesthetic overdoses in people. In recent years, reports of the use of ILE in 
veterinary medicine has increased (Fernandez et al., 2011; Epstein et al., 2013; Bates et al., 2013) and is 
advocated by the VPIS and the Animal Poison Control Center (APCC) for toxicoses associated with fatsoluble 
agents. 
The exact mechanism of action for ILE has yet to be determined. The “lipid sink” theory has been proposed as 
a possible mechanism as well as direct cardiovascular effects (Fettiplace et al., 2015; Rothschild L et al. 2010). 
During infusion of ILE, a lipid phase in the aqueous portion of the blood is created, acting as a sink for lipophilic 
drugs, preferentially pulling them out, or keeping them out, of the tissues (Fettiplace et al., 2015). Its direct 
cardiovascular effect involves providing a source of energy to the myocardial cells. The use of ILE for the 
treatment of lipophilic drug toxicity is increasing. French et al., 2001, suggested that lipid soluble toxicants 
with a partition coefficient (LogP) greater than 1 or 2 and a high volume of distribution (Vd) will respond better 
to ILE therapy. However, ILE’s efficacy in non-local anaesthetic toxicity appears to be heterogenous and the 
quality of evidence to support its use in these cases remains low (Levine et al., 2016). The authors are aware of 
anecdotal reports of itsuse in mycotoxicosis, however, there is only one published case report of the use of ILE 
in dogs with tremorgenic mycotoxin intoxication (Parratt, 2014). In this report, although the dog improved 
with lipid, it was not sufficient to withdraw additional treatment. Roquefortine was confirmed in vomitus in 
this case. 
The purpose of this study is to report the use of ILE in dogs presenting with suspected tremorgenic 
mycotoxicosis, based on signs of intoxication and known ingestion of mouldy food or compost; with the 
hypotheses that, as tremorgenic mycotoxins are lipophilic in nature(Puschner, 2009), the use of ILE may be 
beneficial in these patients. 
 
 
RESULTS  
 
Fifty-three dogs met the criteria for inclusion in the study. Dogs were a median of 3.8 years old (range 0.5-13). 
There were 28 males and 26 females. Common breeds represented included Labrador retrievers (n = 7) and 
beagles (7). Nineteen other breeds were represented by less than 4 dogs each. There were 7 mixed-breed 
dogs.  
Historical complaints and clinical abnormalities at the time of presentation included tremors (n=48), ataxia 
(n=17), vomiting (n=15), hyperthermia (n=15), seizures (n=13), hyperaesthesia (n=8), tachycardia (n=7), 
diarrhoea (n=4), collapse (n=2), abdominal pain (n=1). All dogs were presented primarily for neurological 
signs.  
Duration of signs prior to presentation was not consistently recorded in the medical records, but for the 25/53 
cases that the duration had been recorded it was a median of 2 hours (range 16 minutes to 8 hours). 
Treatment varied between individuals. ILE was used for all the cases included in this study, but never as the 
sole agent. The exact dose and rate of ILE administered was recorded in 46 dogs (87%). In 34/46 (73%) cases 
an intravenous bolus of 1.5ml/kg of a 20% solution of intralipid followed by 0.25-0.5 ml/kg/min constant rate 
infusion for 30-60 minutes was administered. The remaining 12 cases had a variety of doses with 7 treated 
with a bolus followed by infusion, 3 treated with a bolus only and 2 treated with an infusion only. Seven cases 
(15%) had one repeated dose and four (9%) had two repeated doses. The repeated doses ranged from 
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0.25ml/kg to 1.5 ml/kg and were always the same as the initial bolus dose that was administered in each case. 
Benzodiazepines (diazepam or midazolam) were administered in 38/53  (71%) cases, intravenous fluid therapy 
in 31/53 (58%) cases, methocarbamol in 22/53 (42%) cases, activated charcoal in 21/53 (40%) cases, 
phenobarbital in 10/53 (19%) cases, propofol in 10/53 (19%) cases, maropitant in 5/53 (9%) cases, 
medetomidine in 5/53 (9%) cases, apomorphine in 4/53 (8%) cases, opioids in 4/53 (8%) cases, glucose in 2/53 
(4%) cases, mannitol in 1/53 (2%) case and co-amoxiclav in 1/53 (2%) case. The timing that ILE was given in 
relation to the timing of other drugs or intravenous fluid therapy ranged and was not consistently recorded. In 
most cases where diazepam was used, this was the first drug to be administered. However, it appeared that 
diazepam alone was never sufficient to control the signs and, as a result, administration of additional drugs 
was deemed necessary. This agrees with previous reports suggesting that diazepam alone is not usually 
effective in mycotoxicosis cases (Boysen et al., 2002; Young et al., 2003). 
Hospitalisation time at the clinic was a median of 12 hours (range 3-72). In 51/53 (96%) cases there was clinical 
improvement recorded in the clinical notes following ILE. The time that clinical signs took to improve or 
resolve after ILE was a median of 4 hours (range 30 minutes to 36 hours). In 23/53 (43%) there was complete 
resolution of the signs; 12 of these cases were discharged to their primary care vets and 11 of them were 
discharged home. From the cases with complete resolution of signs, five had a repeated dose of ILE. 
In total, 19 dogs (36%) were discharged home, 33 dogs (62%) were transferred back to the primary care vet 
and one dog was euthanased due to the lack of improvement and financial restrictions. In one dog, no clinical 
information was recorded in the clinical records after administration of ILE. This dog was discharged to its 
primary care vet. For the 33 dogs that were discharged to the primary care vet, no follow up information is 
available. 
 
The results of this study suggest that the median time to clinical improvement in dogs with suspected 
tremorgenic mycotoxicosis treated with ILE is 4 hours. This compares favourably with previous reports which 
suggest that signs resolve completely within 24 – 96 hours (Barker et al., 2013). There is limited information 
about the natural progression of this disease, and clinical experience suggests that signs improve over variable 
periods of time.  The improvement seen in these cases may have been natural progression of disease. The 
prognosis for dogs treated for tremorgenic mycotoxins is reportedly excellent and this was confirmed in this 
study with only one dog being euthanased. The administration of ILE seems to be associated with a beneficial 
effect in the short term in this population of animals; it appears that treatment with lipid resulted in reduced 
recovery time in dogs with tremorgenic mycotoxicosis, compared to expected recovery time based on 
literature reports (Barker et al., 2013; Young et al., 2003).  No adverse effects were recorded during the 
infusion or up to the time of discharge. 
There are a number of considerations that need to be taken into account for this study.  Due to the 
retrospective nature of the study some of the data were not consistently recorded in the medical records. 
Importantly long-term follow-up was not available, however all dogs, except for one, were considered to have 
improved and were clinically stable at the time of discharge. The timing ofthe ILE administration in 
relationtothe timing ofthe other drugs or intravenous fluid therapy ranged and was not always recorded; 
hence it would be hard to confirm that it was solely the ILE that resulted in the clinical improvement in these 
cases. Further to this, interactions between ILE and standard treatments are not currently known, but it is 
likely that any lipophilic drug, including diazepam, phenobarbital and propofol, will have minimal action during 
infusion of ILE. 
The dosage of ILE used varied between the cases and was not always recorded. However, in most cases 
standard protocols were followed and included an intravenous bolus of 1.5 ml/kg of a 20% ILE, followed by a 
constant rate infusion CRI of 0.25-0.5 ml/kg/min for 30-60 minutes, which was repeated as necessary. 
DISCUSSION 
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Reported dose ranges in the literature include boluses of 1.5 ml/kg-2.0 ml/kg over 2-15 minutes, then as a CRI 
0.06 ml/kg/min to 0.5 ml/kg/min for multiple hours (Gwaltney-Brant, 2012). No maximum daily dose has been 
determined in veterinary patients (Kuo et al., 2013). 
Methocarbamol was used in 40% of cases to control the tremors. The beneficial use of methocarbamol in 
suspected mycotoxicosis cases has been reported previously (Schell, 2010). As tremors may last for several 
days, oral doses of methocarbamol may be continued after the dog is discharged from the hospital. Onset of 
its action is reportedly 30 minutes and its peak effect is 1-2 hours post oral administration. It is possible that 
the improvement seen in some of the dogs was due solely to methocarbamol administration. 
Finally, the diagnosis of mycotoxicosis in these cases was presumptive and was based on the history and 
clinical signs. Definitive diagnosis is difficult and not commonly reached. This is mainly due to the fact that the 
results cannot be obtainable in a clinically relevant timeframe and that tremorgenic mycotoxicosis is always 
treated empirically. Definitive diagnosis involves analysis of vomitus or stomach contents, blood, urine, or the 
suspected contaminated material. Analytic methods include identification of the mould through culture of the 
organism or detection of the toxins themselves (Eriksen et al. 2010; Rundberget et al., 2002; Young et al., 
2003). Liquid chromatography has also been used to screen for the specific toxins penitrem A and roquefortine 
in serum (Puschner, 2009) and urine samples (Tiwary, 2009). These tests are available from some specialised 
diagnostic laboratories. On necropsy, penitrem A has been isolated from the liver, kidney, and brain (Eriksen et 
al., 2010). 
Even though no acute adverse effects of this therapy were reported in any of the dogs included in this study, 
these have been rarely reported. Potential complications that have not been reported in dogs include sepsis 
secondary to bacterial contamination and thrombophlebitis (Kirsten et al., 2012). In people, lipaemia, 
hepatosplenomegaly, jaundice, haemolysis, coagulopathy, fat emboli, and thrombocytopenia are potential 
concerns (Kirsten et al., 2012). In addition, hypersensitivity reactions and possible interference with other 
drugs can be seen (Gwaltney-Brant, 2012). In a case series, one dog had swelling and pain associated with 
extravasation of the ILE (Bates et al., 2013).There is a single case report of a cat which presented with 
persistent gross lipaemia and suspected corneal lipidosis following treatment for ivermectin toxicity with ILE 
(Seitz et al., 2016). Since there are no current studies evaluating the safety of ILE use in acute toxicities (Kuo et 
al., 2013), owners should be informed of its off-label use (Haworth et al., 2012). 
The results of this study indicate that ILE may be a valuable addition to the clinician’s treatment options for 
suspected exposure to tremorgenic mycotoxins. Prospective evaluation of this therapy is warranted to clarify 
whether clinical signs are more rapidly resolved through the use of ILE versus standard therapies. The use of a 
scoring system to quantify severity of signs such as that reported for use in cats with permethrin toxicity by 
Peacock et al., 2015, would be useful to allow comparison of therapies as well as evaluating the clinical course 
of disease. Further research needs to be conducted in a standardised manner in order to determine specifics 
for ILE dosing, most effective time period for administration, length of administration, and which patients are 
most likely to respond. As this is a toxicity that is most commonly seen in first opinion practice creating 
methods by which randomised clinical trials are easily performed is required. 
 
 
METHODS & MATERIALS 
 
Criteria for Selection of Cases 
Medical records of all dogs treatedat a Vets Now (out-of-hours emergency-care service provider) clinic 
between November 2012 and November 2016, in which ILE had been used, were reviewed. Cases were eligible 
for inclusion in the study if the dog had been treated with ILE and had a highly suspicious diagnosis of 
mycotoxicosis from the history and the physical examination findings. Cases were considered to be highly 
suspicious for mycotoxicosis if the following criteria were met: peracute onset of neurological signs with or 
without gastrointestinal signs AND known ingestion of mouldy food/ compost according to the owner. For the 
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purposes of this study, when duration of signs prior to presentation is recorded as “few hours”, this is 
considered to be less than 6 hours.  
 
Procedures 
Data obtained from the medical records included age, breed, presenting signs, duration of signs prior to 
presentation, treatment, progress during hospitalisation, hospitalisation time and outcome at the time of 
discharge (dead, alive and discharged home or alive and discharged to primary care veterinary practice). Due 
to the nature of out-of-hours veterinary care in the UK, long-term follow-up information was not available, 
since all dogs were discharged either to the owners careor to their primary care veterinary practice by the end 
of the shift, if they were considered to be stable enough to travel. 
Data was entered into a spreadsheet and cases were evaluated by two of the authors (FK and LT) Data were 
extracted into a Statistical Package (SPSS v 23.0). Data are presented descriptively. 
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